AneuVysion, which utilizes patented fluorescence in situ hybridization (FISH) technology applied to uncultured amniocytes, provides detection of trisomies 13, 18, and 21 (Down syndrome) and sex chromosome aneusomies in as little as 24 hours.
Genetic Probes are used for detection of chromosomal anomalies at prenatal, postnatal and preimplantation stage. These probes enable rapid, sensitive and specific dection, identification & characterization of chromosome anomalies.
Abbott Molecular offers a wide range of Vysis DNA Fluorescence in situ Hybridization (FISH) products for the effective and rapid identification of genetic aberrations associated with hematopoietic disorders.
The PathVysion HER-2 DNA Probe Kit II (PathVysion Kit II) is designed to detect amplification of the HER-2/neu gene via fluorescence in situ hybridization (FISH) in formalin-fixed, paraffin-embedded human breast and gastric cancer tissue specimens.
The detection of genetic aberrations in solid tumors with DNA Fluorescence in situ Hybridization (FISH) probe technology is a powerful means to diagnose and more efficiently treat a wide range of cancers. Vysis offers a comprehensive line of direct labeled DNA probes for solid tumor assessment.
The UroVysion® Bladder Cancer Kit (UroVysion Kit) is FDA approved and designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer.